Zentiva Pharma Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Zentiva Pharma Gmbh

Patent Number:
Title:
Combination Therapy For The Treatment Of Ovarian Cancer
Opposition Date:
Aug 28, 2024
Patent Number:
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Applicant:
Opposition Date:
Sep 16, 2019

Want to track Zentiva Pharma Gmbh?

Feel free to send us a message here and we will get back to you